Sodium benzoate - SyneuRx
Alternative Names: Benzoate - SyneuRx; Clozaben; NaBen; SND 51; SND-11; SND-12; SND-13; SND-14; TannquilynneLatest Information Update: 18 Jun 2024
At a glance
- Originator SyneuRx International (Taiwan) corp
- Class Antidementias; Antifungals; Antipsychotics; Antiseptics; Benzoates
- Mechanism of Action D amino acid oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Schizophrenia
- Phase II Psychotic disorders
- No development reported Dementia
Most Recent Events
- 18 Jun 2024 Chemical structure information added
- 29 Nov 2023 SyneuRx International terminates due to commercial strategy a phase-II/III clinical trial in Schizophrenia (In adults, Adjuvant therapy) in USA (PO) (NCT02261519)
- 26 Oct 2023 SyneuRx International (Taiwan) corp terminates a phase IIb/III trials for Schizophrenia (In adolescents, Adjuvant therapy) in USA and Taiwan (PO) (NCT01908192)